The ruling on glyphosate labeling has sparked outrage among advocates for pesticide regulation and cancer victims
Category: Health
On a day that many advocates had anticipated would bring justice for cancer victims, the Supreme Court delivered a ruling that instead favored Monsanto, the maker of Roundup weedkiller. The court's decision overturned a $1.25 million verdict awarded to John Durnell, a cancer patient who argued that the company failed to provide adequate warning about the risks associated with its product, which contains glyphosate. This ruling has reignited a fierce debate over the safety and regulation of pesticides in the United States.
The core of the legal battle revolves around the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), which dictates that the Environmental Protection Agency (EPA) must approve any warning labels on pesticides. In a 7-2 decision, the Supreme Court determined that Durnell’s state-law claim was preempted by federal law, as the EPA had repeatedly concluded that glyphosate does not warrant a cancer warning. Justice Brett Kavanaugh, who wrote the majority opinion, emphasized that Durnell’s claim would necessitate a label that was "in addition to or different from" what the EPA required, which is prohibited under FIFRA.
This ruling has been met with disappointment and anger from advocates who argue that it undermines the rights of individuals seeking justice for health issues allegedly caused by pesticides. Durnell, diagnosed with non-Hodgkin lymphoma in 2018 after using Roundup for over two decades, filed his failure-to-warn claim in 2019. A Missouri jury initially sided with him, awarding him $1.25 million in damages. Yet, the Supreme Court’s ruling has effectively barred similar claims, reinforcing the notion that federal regulations take precedence over state laws in this area.
In a statement following the ruling, Christopher Seeger, proposed class counsel in a $7.25 billion settlement negotiated with Monsanto for Roundup cancer claims, expressed his frustration. “This Supreme Court ruling wrongly slams the courthouse door on Americans sickened by pesticides, and it highlights why we negotiated a $7.25 billion settlement that guarantees compensation to Roundup victims regardless of today’s decision,” Seeger stated. He urged those opposing the settlement to reconsider, emphasizing the need for swift justice for cancer victims.
The ruling is rooted in the complex regulatory framework established by FIFRA, which governs the sale and labeling of pesticides in the United States. Under FIFRA, manufacturers must submit safety data and proposed labeling to the EPA, which reviews these materials to determine whether the pesticide poses an unreasonable risk to human health. The EPA has consistently approved the labeling of glyphosate-based products without a cancer warning, citing extensive research that supports their safety when used as directed.
Since 1974, the EPA has repeatedly concluded that glyphosate does not warrant a cancer warning. This consistent finding has been a point of contention for those advocating for stricter regulations on pesticide use. The Trump administration, in its efforts to bolster agricultural interests, has also sided with Bayer, Monsanto’s parent company, in various legal matters. Notably, the administration filed an amicus brief with the Supreme Court in support of Bayer, a move that has drawn criticism from advocates concerned about pesticide safety.
The ruling has galvanized the MAHA (Mothers Against Herbicide Abuse) movement, which seeks to raise awareness about the potential dangers of glyphosate and other pesticides. Grassroots supporters have worked tirelessly to influence legislation, pushing to remove language in the House farm bill that would protect pesticide manufacturers from liability. Their efforts, though met with resistance from some lawmakers and the White House, have gained traction among constituents concerned about health risks associated with pesticide exposure.
MAHA advocates have expressed frustration with Health Secretary Robert F. Kennedy Jr., criticizing him for not doing enough to advance their priorities on pesticides and vaccines. The movement has gained momentum, leading to rallies and protests, including one outside the Supreme Court in response to the ruling favoring Bayer. These advocates argue that the health risks associated with glyphosate must be addressed more rigorously, calling for transparency and accountability in pesticide regulation.
As the dust settles from the Supreme Court's ruling, the future of glyphosate regulation remains uncertain. The EPA is expected to reexamine the safety of glyphosate by an October deadline, a process that could lead to changes in how the chemical is regulated. Advocates are hopeful that new evidence may surface, prompting a reevaluation of glyphosate's safety profile.
In February, President Trump issued an executive order invoking the Defense Production Act to protect the manufacturing of glyphosate-based herbicides. This move was seen as a way to support agricultural interests, but it has also sparked ire among those advocating for stricter pesticide regulations. The tension between supporting farmers and addressing public health concerns continues to complicate the regulatory environment surrounding glyphosate.
The Supreme Court's ruling has been framed by Bayer CEO Bill Anderson as a victory for American farmers. In a statement, he noted that the decision provides regulatory certainty and is beneficial for those who cultivate crops using Roundup. “This litigation has enormous costs for the company and has impacted public trust,” Anderson said. “The decision brings overdue justice on an issue that should have been clarified much earlier. It’s time to put it behind us.”
As Bayer moves forward, the company is pursuing final approval for a $7.25 billion class-action settlement aimed at resolving glyphosate cancer claims. This settlement is seen as a necessary step to mitigate the extensive litigation that has plagued the company for years. The proposed settlement is expected to provide compensation to thousands of individuals who have alleged harm from glyphosate exposure.
The implications of this ruling extend beyond the courtroom. For consumers and farmers alike, the debate over glyphosate's safety and regulation will likely continue to shape agricultural practices and public health discussions for years to come.